Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 10—October 2020
Research

Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China

Feixue Wei1, Yingying Su1, Xuelian Cui, Xiaojuan Yu, Yafei Li, Qiaoqiao Song, Kai Yin, Shoujie Huang, Mingqiang Li, Jun Zhang, Ting WuComments to Author , and Ningshao Xia
Author affiliations: Xiamen University School of Public Health, Xiamen, China (F. Wei, Y. Su, X. Yu, Y. Li, Q. Song, S. Huang, J. Zhang, T. Wu, N. Xia); Liuzhou Center for Disease Control and Prevention, Liuzhou, China (X. Cui, K. Yin, M. Li)

Main Article

Table 2

Incidence rate of sequential HPV infection at the genital site for participants with or without previous anal HPV infection of the same type by sex in Liuzhou, China, 2014–2016*

HPV status at anal site before genital infection Positive for HPV type at genital site
Men
Women
No. Incidence/1,000 person-months (95% CI) HR (95% CI) No. Incidence/1,000 person-months (95% CI) HR (95% CI)
Any HPV
Negative 131 9.5 (8.0–11.2) 1.0 221 9.3 (8.1–10.6) 1.0
Positive
 3
 6.9 (2.2–21.4)
 0.7 (0.2–1.9)
20
 15.0 (9.7–23.3)
 1.9 (1.2–3.1)
High-risk HPV
Negative 116 8.4 (7.0–10.0) 1.0 201 8.4 (7.3–9.7) 1.0
Positive
 2
 5.8 (1.4–23.0)
 0.6 (0.2–1.9)
17
 13.5 (8.4–21.7)
 1.9 (1.1–3.1)
9V-HPV
Negative 67 4.8 (3.8–6.1) 1.0 98 4.1 (3.3–4.9) 1.0
Positive
 3
 9.3 (3.0–28.9)
 1.5 (0.5–4.6)
5
 7.3 (3.0–17.6)
 2.1 (0.8–5.2)
HPV 16/18
Negative 30 2.1 (1.5–3.0) 1.0 37 1.5 (1.1–2.1) NE
Positive
 1
 28.6 (4.0–203.2)
 21.6 (2.4–197.9)
0
 0
 NE
HPV 6/11
Negative 16 1.1 (0.7–1.9) 1.0 23 0.9 (0.6–1.4) 1.0
Positive
 1
 10.7 (1.5–75.7)
 12.3 (1.5–98.7)
2
 21.4 (5.3–85.4)
 34.4 (7.6–155.2)
HPV 6
Negative 13 0.9 (0.5–1.6) NE 13 0.5 (0.3–0.9) 1.0
Positive
 0
 0
 NE
2
 24.5 (6.1–97.8)
 65.3 (14.1–302.2)
HPV 11
Negative 3 0.2 (0.1–0.7) 1.0 10 0.4 (0.2–0.8) NE
Positive
 1
 14.7 (2.1–104.7)
 100.7 (9.1–1,117.4)
0
 0
 NE
HPV 16
Negative 18 1.3 (0.8–2.0) 1.0 25 1.1 (0.7–1.6) NE
Positive
 1
 44.5 (6.3–316.0)
 51.1 (6.7–387.8)
0
 0
 NE
HPV 18
Negative 12 0.9 (0.5–1.5) NE 13 0.5 (0.3–0.9) NE
Positive
 0
 0
 NE
0
 0
 NE
HPV 31
Negative 5 0.4 (0.1–0.9) 1.0 5 0.2 (0.1–0.5) NE
Positive
 1
 31.6 (4.4–224.2)
 7.8 (0.1–556.0)
0
 0
 NE
HPV 33
Negative 3 0.2 (0.1–0.7) NE 9 0.4 (0.2–0.7) 1.0
Positive
 0
 0
 NE
1
 20.3 (2.9–144.1)
 109.0 (12.7–937.1)
HPV 35
Negative 3 0.2 (0.1–0.7) NE 7 0.3 (0.1–0.6) NE
Positive
 0
 0
 NE
0
 0
 NE
HPV 39
Negative 21 1.5 (1.0–2.3) NE 24 1.0 (0.7–1.5) 1.0
Positive
 0
 0
 NE
2
 15.7 (3.9–62.7)
 17.5 (4.1–74.7)
HPV 45
Negative 4 0.3 (0.1–0.8) NE 4 0.2 (0.1–0.4) NE
Positive
 0
 0
 NE
0
 0
 NE
HPV 51
Negative 6 0.4 (0.2–1.0) NE 28 1.2 (0.8–1.7) 1.0
Positive
 0
 0
 NE
2
 15.4 (3.9–61.6)
 12.3 (2.7–55.0)
HPV 52
Negative 28 2.0 (1.4–3.0) NE 50 2.2 (1.7–3.0) 1.0
Positive
 0
 0
 NE
9
 22.6 (11.8–43.5)
 13.9 (6.8–28.5)
HPV 56
Negative 4 0.3 (0.1–0.8) NE 18 0.7 (0.5–1.2) 1.0
Positive
 0
 0
 NE
1
 14.2 (2.0–100.5)
 20.5 (2.7–155.3)
HPV 58
Negative 12 0.9 (0.5–1.6) NE 27 1.2 (0.8–1.7) 1.0
Positive
 0
 0
 NE
2
 7.3 (1.8–29.1)
 6.0 (1.4–25.3)
HPV 59
Negative 14 1.0 (0.6–1.7) NE 22 0.9 (0.6–1.4) NE
Positive
 0
 0
 NE
0
 0
 NE
HPV 66
Negative 2 0.1 (0.0–0.6) NE 5 0.2 (0.1–0.5) 1.0
Positive
 0
 0
 NE
1
 46.2 (6.5–327.6)
 339.2 (30.2–3,815.6)
HPV 68
Negative 0 0 NE 1 0.0 (0.0–0.3) NE
Positive 0 0 NE 0 0 NE

*HRs and 95% CIs of sequential grouped HPV infection were calculated based on individual results. 9V-HPV, 9-valent vaccine-related HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58); high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68); HPV, human papillomavirus; HR, hazard ratio; NE, not estimable.

Main Article

1These authors contributed equally to this article.

Page created: June 21, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external